ARTIVION, INC.

AORT

ARTIVION, INC.

AORT

Insider Sentiment (TTM):

Last Purchase:2025-03-05Last Sale:2026-06-11Shares Purchased (TTM):0Shares Sold (TTM):419,138

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:43,083,482Shares Outstanding:48,074,000Institutional Ownership Pct.:89.62%

Earnings Market Reaction:

Filing Date:2026-08-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	77	56	65	73	53	38	53	56	55	51	59	53
Accounts Receivable Net Current	98	92	90	88	91	88	79	76	74	74	72	64
Other Receivables Net Current	13	14	14	9	10	8	6	2	5	2	2	4
Inventory Net	103	98	92	91	87	82	80	84	81	82	82	79
Prepaid Expense And Other Assets Current	27	45	43	22	25	20	19	19	20	17	16	17
Assets Current	371	358	358	337	319	287	290	288	285	277	281	267
Goodwill	350	252	254	254	254	245	241	249	244	245	247	243
Finite Lived Intangible Assets Net	149	120	124	126	129	128	128	135	135	138	143	143
Operating Lease Right Of Use Asset	37	35	35	39	40	39	40	41	42	42	44	43
Property Plant And Equipment Net	74	68	65	41	40	38	36	38	37	38	38	37
Property Plant And Equipment And Finance Lease Rig…	-	-	-	-	-	-	-	-	-	-	38	-
Other Intangible Assets Net	75	35	33	30	29	29	28	30	29	30	30	29
Deferred Income Tax Assets Net	1	1	1	1	1	1	1	1	3	1	1	4
Other Assets Noncurrent	15	16	15	29	27	25	24	21	14	13	9	8
Assets	1,072	883	885	858	838	791	789	803	790	784	792	775
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	21	18	16	16	19	12	18	11	12	10	13	11
Employee Related Liabilities Current	18	14	22	18	16	12	18	15	14	11	19	14
Accrued Liabilities Current	16	17	16	12	11	12	12	16	16	16	10	10
Interest Payable Current	7	4	5	6	6	7	8	-	-	-	2	-
Taxes Payable Current	6	7	7	2	3	2	3	4	2	2	4	9
Business Combination Contingent Consideration Liab…	25	21	21	19	-	-	0	-	-	-	-	-
Operating Lease Liability Current	5	5	5	5	5	5	4	5	3	3	3	4
Finance Lease Liability Current	-	1	1	1	1	1	1	-	-	-	1	-
Other Liabilities Current	7	3	5	4	3	1	1	1	2	2	2	4
Long Term Debt Current	-	0	0	0	0	0	0	100	0	0	1	2
Liabilities Current	107	93	102	86	67	52	67	153	51	46	58	55
Long Term Debt Noncurrent	363	215	215	215	216	315	314	214	313	313	306	306
Business Combination Contingent Consideration Liab…	72	41	40	37	53	50	53	52	48	46	64	62
Operating Lease Liability Noncurrent	36	34	34	38	39	39	40	41	42	43	44	43
Deferred Income Tax Liabilities Net	26	28	24	22	23	22	20	19	22	22	22	20
Deferred Compensation Liability Classified Noncurr…	11	10	9	9	9	8	8	8	7	7	7	6
Finance Lease Liability Noncurrent	-	3	3	3	3	3	3	3	3	3	3	3
Other Liabilities Noncurrent	9	9	9	9	9	8	8	8	8	8	7	8
Liabilities	626	433	437	419	418	497	513	498	494	489	511	503
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	1	1	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	536	526	517	509	497	389	377	373	368	363	356	351
Retained Earnings Accumulated Deficit	-64	-50	-51	-54	-60	-62	-61	-45	-42	-40	-48	-44
Accumulated Other Comprehensive Income Loss Net Of…	-12	-12	-3	-2	-3	-19	-25	-10	-16	-14	-12	-21
Treasury Stock Common Value	-15	-15	-15	-15	-15	-15	-15	-15	-15	-15	-15	-15
Stockholders Equity	446	450	448	439	420	294	276	305	295	295	282	272
Liabilities And Stockholders Equity	1,072	883	885	858	838	791	789	803	790	784	792	775
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	-	-	-	0.01	-
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	-	-	-	5	-
Preferred Stock Shares Issued	0	0	0	0	0	0	0	-	-	-	0	-
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	-	-	-	0.01	-
Common Stock Shares Authorized	75	75	75	75	75	75	75	75	75	75	75	75
Common Stock Shares Issued	50	50	49	49	49	44	43	43	43	43	43	43
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	43
Treasury Stock Common Shares	1	1	1	1	1	1	1	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-12.67%	-7.08%	-0.51%	-	-	-	-	-	-	-	-	-
2025	7.88%	13.75%	14.51%	7.28%	0.27%	5.98%	3.99%	3.21%	-4.12%	-3.01%	0.29%	-32.28%
2024	-0.72%	7.91%	15.61%	9.22%	8.05%	6.52%	2.82%	1.01%	6.79%	-3.86%	-9.76%	16.14%
2023	-	-	-	-	-	-	24.10%	26.56%	28.18%	-2.57%	0.94%	16.08%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.47	3.86	3.53	3.93	4.78	5.53	4.34	1.88	5.63	6.04	4.85	4.86
Quick Ratio	2.26	2.32	2.20	2.62	3.11	3.58	2.86	1.21	3.65	3.88	3.16	3.11
Working Capital	264.45M	264.82M	256.53M	251.66M	252.15M	235.36M	223.26M	135.12M	234.38M	230.96M	222.81M	212.15M
Leverage & Debt
Debt to Equity	1.41	0.96	0.97	0.96	1.00	1.69	1.86	1.64	1.68	1.66	1.81	1.85
Interest Coverage TTM	0.85	1.54	1.27	0.84	0.53	0.46	1.13	1.28	1.16	1.29	0.23	0.27
Debt Ratio	0.58	0.49	0.49	0.49	0.50	0.63	0.65	0.62	0.63	0.62	0.64	0.65
Efficiency & Turnover
Asset Turnover TTM	0.49	0.55	0.53	0.51	0.50	0.50	0.49	0.49	0.48	0.48	0.46	0.45
Days Sales Outstanding TTM	73.30	71.49	69.98	70.73	74.49	75.84	71.05	66.36	67.15	67.93	68.88	65.23
Receivables Turnover TTM	4.98	5.11	5.22	5.16	4.90	4.81	5.14	5.50	5.44	5.37	5.30	5.60
Per Share Metrics
Diluted EPS TTM	-0.07	0.24	0.21	-0.19	-0.40	-0.51	-0.32	-0.02	-0.20	-0.20	-0.75	-0.60
Free Cash Flow Per Share TTM	-0.19	0.30	0.02	0.37	0.17	-0.01	0.27	0.25	0.19	0.22	0.22	-0.03
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	64.37%	64.55%	64.40%	64.50%	63.99%	63.94%	64.03%	64.53%	64.63%	64.75%	64.74%	64.45%
Operating Profit Margin TTM	4.38%	8.15%	7.65%	6.09%	4.34%	4.03%	10.01%	10.23%	8.95%	9.48%	1.62%	1.97%
Net Profit Margin TTM	-0.67%	2.55%	2.21%	-2.16%	-4.43%	-5.49%	-3.44%	-0.22%	-2.22%	-2.61%	-8.67%	-7.23%
Growth Metrics
Net Revenue Growth (1Y)	16.40%	17.59%	13.59%	9.81%	7.44%	5.94%	9.75%	13.29%	14.68%	15.13%	12.82%	8.27%
Net Income Growth (1Y)	-82.35%	-154.63%	-173.12%	974.15%	114.38%	122.31%	-56.47%	-96.53%	-70.61%	-67.19%	59.91%	-40.80%
EPS Growth (1Y)	-83.89%	-147.99%	-167.22%	851.59%	101.74%	117.35%	-57.45%	-96.61%	-71.26%	-67.87%	57.12%	-41.91%
Valuation Metrics
P/E TTM	-344.62	150.60	211.68	-218.78	-76.83	-48.51	-89.19	-1,308.92	-127.83	-90.77	-23.74	-25.25
P/B TTM	2.45	3.91	4.61	4.56	3.28	3.53	4.31	3.66	3.62	2.96	2.59	2.28
P/S TTM	2.31	3.84	4.69	4.73	3.40	2.66	3.07	2.89	2.84	2.37	2.06	1.82
Market Cap	1.09B	1.76B	2.07B	2.00B	1.38B	1.04B	1.19B	1.11B	1.07B	873.70M	728.48M	619.76M
Enterprise Value	1.38B	1.92B	2.22B	2.14B	1.54B	1.32B	1.45B	1.37B	1.33B	1.14B	977.11M	873.70M
Calculated Values
Free Cash Flow TTM	-9.16M	14.58M	839.00K	17.50M	7.66M	-439.00K	11.05M	10.50M	7.85M	8.97M	9.07M	-1.41M
Net Debt	286.11M	160.45M	150.93M	142.16M	162.85M	277.72M	261.49M	257.80M	258.54M	262.16M	248.62M	253.95M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-11Sale

Owner: Green, Andrew M

Title: SVP, Regulatory and Quality

Shares: 44,001

Price/Share: $20.70

Value: $910,820.70

Shares Owned: 60,259

Relationship: Officer

Ownership: Direct

2026-03-04Sale

Owner: Holloway, Jean F

Title: SVP, General Counsel

Shares: 8,962

Price/Share: $38.00

Value: $340,556.00

Shares Owned: 185,095

Relationship: Officer

Ownership: Direct

2026-03-03Sale

Owner: Stanton, Marshall S.

Title: SVP, Clinical & MD Affair

Shares: 2,149

Price/Share: $37.78

Value: $81,189.22

Shares Owned: 60,097

Relationship: Officer

Ownership: Direct

2026-03-03Sale

Owner: Davis, John E

Title: Chief Commercial Officer

Shares: 4,573

Price/Share: $37.78

Value: $172,767.94

Shares Owned: 230,794

Relationship: Officer

Ownership: Direct

2026-03-03Sale

Owner: Mackin, James P

Title: President & CEO

Shares: 17,887

Price/Share: $37.78

Value: $675,770.86

Shares Owned: 947,275

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-11	Green, Andrew M	Officer	SVP, Regulatory and Quality	Direct	Sale	44,001	20.70	$910,820.70	60,259	4
2026-03-04	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	8,962	38.00	$340,556.00	185,095	4
2026-03-03	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	2,149	37.78	$81,189.22	60,097	4
2026-03-03	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	4,573	37.78	$172,767.94	230,794	4
2026-03-03	Mackin, James P	Officer	President & CEO	Direct	Sale	17,887	37.78	$675,770.86	947,275	4
2026-03-03	Berry, Lance A	Officer	EVP, COO, CFO & Treasurer	Direct	Sale	6,316	37.78	$238,618.48	210,827	4
2026-03-03	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	901	37.78	$34,039.78	139,088	4
2026-03-02	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	2,183	38.02	$82,997.66	170,105	4
2026-03-02	Mackin, James P	Officer	President & CEO	Direct	Sale	14,911	38.02	$566,916.22	848,214	4
2026-03-02	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	2,784	38.02	$105,847.68	206,522	4
2026-03-02	Berry, Lance A	Officer	EVP, COO, CFO & Treasurer	Direct	Sale	5,178	38.02	$196,867.56	176,269	4
2026-03-02	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	1,513	38.02	$57,524.26	40,408	4
2026-03-02	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	641	38.02	$24,370.82	132,514	4
2026-02-24	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	2,075	35.69	$74,056.75	188,868	4
2026-02-24	Mackin, James P	Officer	President & CEO	Direct	Sale	13,936	35.69	$497,375.84	766,095	4
2026-02-24	Berry, Lance A	Officer	EVP, COO, CFO & Treasurer	Direct	Sale	4,485	35.69	$160,069.65	143,965	4
2026-02-24	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	1,259	35.69	$44,933.71	41,921	4
2026-02-24	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	830	35.69	$29,622.70	127,497	4
2026-02-24	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	1,668	35.69	$59,530.92	152,203	4
2025-12-15	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	5,000	45.11	$225,550.00	193,842	4
2025-12-08	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	4,572	44.42	$203,088.24	130,058	4
2025-12-03	Mackin, James P	Officer	President & CEO	Direct	Sale	30,921	45.46	$1,405,668.66	800,993	4
2025-12-03	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	7,315	45.30	$331,369.50	156,093	4
2025-12-02	Mackin, James P	Officer	President & CEO	Direct	Sale	30,921	45.56	$1,408,760.76	800,993	4
2025-11-21	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	47,376	45.13	$2,138,078.88	44,753	4
2025-11-20	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	15,276	44.25	$675,963.00	44,753	4
2025-11-18	Hoff, Elizabeth A	Director	-	Direct	Sale	4,200	45.10	$189,420.00	27,189	4
2025-11-17	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	6,394	45.17	$288,816.98	198,842	4
2025-11-17	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	6,394	45.17	$288,816.98	163,408	4
2025-11-17	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	6,000	45.73	$274,380.00	135,380	4
2025-11-13	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	5,761	45.86	$264,199.46	163,408	4
2025-11-13	Mackin, James P	Officer	President & CEO	Direct	Sale	34,210	45.86	$1,568,870.60	800,993	4
2025-11-13	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	6,563	45.86	$300,979.18	198,842	4
2025-11-13	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	4,993	45.86	$228,978.98	56,641	4
2025-11-13	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	3,482	45.86	$159,684.52	141,380	4
2025-11-11	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	10,000	46.18	$461,800.00	169,169	4
2025-11-10	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	3,373	44.62	$150,503.26	205,405	4
2025-11-10	Mackin, James P	Officer	President & CEO	Direct	Sale	17,580	44.62	$784,419.60	835,203	4
2025-11-10	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	1,789	44.62	$79,825.18	144,862	4
2025-11-10	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	2,566	44.62	$114,494.92	61,634	4
2025-08-27	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	18,200	44.02	$801,164.00	64,200	4
2025-08-25	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	10,000	44.37	$443,700.00	172,129	4
2025-08-15	Mackin, James P	Officer	President & CEO	Direct	Sale	12,500	42.32	$529,000.00	852,783	4
2025-08-12	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	23,356	43.02	$1,004,775.12	172,129	4
2025-08-12	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	10,802	43.67	$471,723.34	208,778	4
2025-08-08	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	7,992	38.49	$307,612.08	146,651	4
2025-06-17	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	15,000	29.50	$442,500.00	64,200	4
2025-06-13	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	26,132	28.44	$743,194.08	79,200	4
2025-05-27	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	8,748	29.00	$253,692.00	178,510	4
2025-05-23	Semedo, Anthony B.	Director	-	Direct	Sale	2,600	28.47	$74,022.00	39,384	4/A
2025-05-21	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	9,926	29.00	$287,854.00	187,258	4
2025-05-09	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	10,548	29.13	$307,263.24	105,332	4
2025-03-11	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	18,020	23.61	$425,452.20	197,184	4
2025-03-11	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	15,100	23.61	$356,511.00	208,778	4
2025-03-06	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	2,618	24.80	$64,926.40	207,968	4
2025-03-06	Berry, Lance A	Officer	Executive VP, CFO	Direct	Sale	4,909	24.80	$121,743.20	153,431	4
2025-03-06	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	1,048	24.80	$25,990.40	146,651	4
2025-03-06	Mackin, James P	Officer	President & CEO	Direct	Sale	88,439	24.78	$2,191,518.42	860,368	4
2025-03-06	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	2,124	24.80	$52,675.20	196,112	4
2025-03-06	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	1,603	24.80	$39,754.40	115,880	4
2025-03-05	Semedo, Anthony B.	Director	-	Direct	Purchase	1,500	25.33	$37,995.00	35,659	4
2025-03-05	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	472	25.29	$11,936.88	172,743	4
2025-02-24	Mackin, James P	Officer	President & CEO	Direct	Sale	42,156	27.31	$1,151,280.36	663,882	4
2025-02-24	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	6,457	27.31	$176,340.67	160,631	4
2025-02-24	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	5,335	27.31	$145,698.85	149,799	4
2025-02-24	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	4,687	27.31	$128,001.97	79,845	4
2025-02-24	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	3,323	27.31	$90,751.13	131,141	4
2025-02-24	Berry, Lance A	Officer	Executive VP, CFO	Direct	Sale	3,259	27.31	$89,003.29	75,805	4
2024-12-11	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	8,070	30.12	$243,068.40	153,862	4
2024-12-06	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	4,425	29.05	$128,546.25	135,564	4/A
2024-12-04	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	7,618	30.00	$228,540.00	33,503	4
2024-10-01	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	12,430	26.18	$325,417.40	139,989	4
2024-08-26	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	3,167	26.55	$84,083.85	161,932	4
2024-08-16	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	9,420	25.31	$238,420.20	34,116	4
2024-08-15	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	2,383	25.76	$61,386.08	165,099	4
2024-08-13	Semedo, Anthony B.	Director	-	Direct	Sale	9,709	24.99	$242,627.91	34,159	4
2024-05-10	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	1,250	23.42	$29,275.00	167,482	4
2024-05-09	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	979	23.79	$23,290.41	168,732	4
2024-03-20	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	2,183	20.39	$44,511.37	83,296	4
2024-03-15	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	1,462	20.00	$29,240.00	41,121	4
2024-03-14	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	3,994	20.00	$79,880.00	42,583	4
2024-03-12	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	5,000	19.94	$99,700.00	43,536	4
2024-03-05	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	1,160	18.72	$21,715.20	46,577	4/A
2024-03-05	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	2,380	18.72	$44,553.60	169,711	4/A
2024-03-05	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	1,506	18.72	$28,192.32	85,438	4
2024-03-05	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	1,157	18.72	$21,659.04	48,536	4/A
2024-03-05	Mackin, James P	Officer	President & CEO	Direct	Sale	13,996	18.72	$262,005.12	706,038	4/A
2024-03-05	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	2,022	18.72	$37,851.84	165,690	4/A
2024-03-05	Maney, Rochelle L.	Officer	VP, Quality	Direct	Sale	1,157	18.72	$21,659.04	46,569	4/A
2024-03-05	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	1,152	18.72	$21,565.44	139,989	4/A
2024-03-01	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	1,506	18.72	$28,192.32	85,479	4/A
2024-02-27	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	325	19.83	$6,444.75	46,115	4/A
2024-02-27	Maney, Rochelle L.	Officer	VP, Quality	Direct	Sale	370	19.83	$7,337.10	44,148	4/A
2024-02-27	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	465	19.83	$9,220.95	81,261	4/A
2024-02-27	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	421	19.83	$8,348.43	44,159	4/A
2024-02-27	Tyrs, Florian	Officer	VP, Global Operations	Direct	Sale	339	19.83	$6,722.37	21,558	4
2024-02-27	Mackin, James P	Officer	President & CEO	Direct	Sale	4,837	19.83	$95,917.71	691,416	4/A
2024-02-27	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	325	19.83	$6,444.75	137,563	4/A
2024-02-27	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	584	19.83	$11,580.72	161,988	4/A
2024-02-27	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	485	19.83	$9,617.55	166,367	4/A
2024-02-26	Mackin, James P	Officer	President & CEO	Direct	Sale	30,836	20.27	$625,045.72	650,573	4/A
2024-02-26	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	2,280	20.27	$46,215.60	40,140	4/A
2024-02-26	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	2,134	20.27	$43,256.18	132,436	4/A
2024-02-26	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	2,838	20.27	$57,526.26	155,559	4/A
2024-02-26	Maney, Rochelle L.	Officer	VP, Quality	Direct	Sale	2,282	20.27	$46,256.14	39,214	4/A
2024-02-26	Tyrs, Florian	Officer	VP, Global Operations	Direct	Sale	893	20.27	$18,101.11	21,897	4
2024-02-26	Green, Andrew M	Officer	VP Regulatory	Direct	Sale	2,367	20.27	$47,979.09	38,865	4/A
2024-02-26	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	3,461	20.27	$70,154.47	151,711	4/A
2024-02-26	Stanton, Marshall S.	Officer	SVP, Clinical & MD Affair	Direct	Sale	3,007	20.27	$60,951.89	72,513	4/A
2024-02-20	Mackin, James P	Officer	President & CEO	Direct	Sale	72,069	18.86	$1,359,221.34	539,036	4
2024-02-20	Maney, Rochelle L.	Officer	VP, Quality	Direct	Sale	407	18.87	$7,680.09	29,123	4
2024-02-20	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	1,695	18.87	$31,984.65	122,345	4
2024-02-20	Tyrs, Florian	Officer	VP, Global Operations	Direct	Sale	249	18.87	$4,698.63	16,253	4
2024-02-20	Davis, John E	Officer	Chief Commercial Officer	Direct	Sale	2,556	18.87	$48,231.72	128,177	4
2024-02-20	Getz, Matthew A	Officer	VP, Human Resources	Direct	Sale	1,695	18.87	$31,984.65	28,692	4
2024-02-20	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	3,527	18.87	$66,554.49	131,858	4
2024-01-02	Holloway, Jean F	Officer	SVP, General Counsel	Direct	Sale	21,229	18.00	$382,122.00	133,520	4
2024-01-02	Davis, John E	Officer	Senior VP, Global Sales	Direct	Sale	13,562	18.00	$244,116.00	128,733	4
2023-12-15	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	14,397	19.00	$273,543.00	124,040	4
2023-11-27	Horton, Amy	Officer	VP, Chief Accounting Officer	Direct	Sale	2,101	17.34	$36,431.34	105,599	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

89.62%

Inst. Shares: 43,083,482

Shares Outstanding: 48,074,000

2025-12-31

91.51%

Inst. Shares: 41,487,754

Shares Outstanding: 45,335,000

2025-09-30

85.60%

Inst. Shares: 40,429,207

Shares Outstanding: 47,233,000

2025-06-30

89.86%

Inst. Shares: 39,803,284

Shares Outstanding: 44,296,000

2025-03-31

92.23%

Inst. Shares: 38,949,905

Shares Outstanding: 42,232,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	43,083,482	48,074,000	89.62%
2025-12-31	41,487,754	45,335,000	91.51%
2025-09-30	40,429,207	47,233,000	85.60%
2025-06-30	39,803,284	44,296,000	89.86%
2025-03-31	38,949,905	42,232,000	92.23%
2024-12-31	36,179,619	41,676,000	86.81%
2024-09-30	34,166,581	41,844,000	81.65%
2024-06-30	33,616,751	41,683,000	80.65%
2024-03-31	33,529,477	41,290,000	81.20%
2023-12-31	32,217,960	40,743,000	79.08%
2023-09-30	32,003,510	40,881,000	78.28%
2023-06-30	32,392,768	40,755,000	79.48%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ARTIVION, INC. (AORT) — SEC Financial Statements & Analysis

ARTIVION, INC. (AORT) is a surgical & medical instruments & apparatus company, incorporated in DE. ARTIVION, INC. trades on NYSE as: AORT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ARTIVION, INC. reported a 16.40% year-over-year revenue growth, a Gross Profit Margin of 64.37% (TTM), a Debt-to-Equity ratio of 1.41x, a Price-to-Sales (P/S) ratio of 2.31x (TTM), a Price-to-Book (P/B) ratio of 2.45x (TTM), at a market cap of $1.09B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 16.40%
Gross Profit Margin TTM: 64.37%
Debt To Equity: 1.41x
P/S TTM: 2.31x
P/B TTM: 2.45x
Market Cap: $1.09B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ARTIVION, INC. in?

ARTIVION, INC. (AORT) operates in the Surgical & Medical Instruments & Apparatus industry.

What is AORT's market cap?

ARTIVION, INC. (AORT) has a market capitalization of $1.09B as of 2026-06-30.

What exchange does AORT trade on?

ARTIVION, INC. (AORT) trades on the NYSE.

Where is ARTIVION, INC. incorporated?

ARTIVION, INC. is incorporated in DE.

ARTIVION, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

ARTIVION, INC. (AORT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.
Main Street's price.

ARTIVION, INC. (AORT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.